A 2-pronged approach was used: (1) data on physician prescribing practices was gathered via retrospective chart review of EoE patients prescribed dupilumab and (2) pediatric patients on dupilumab were approached to complete a questionnaire regarding reasons for initiation. During this time, 42 ...
A 2-pronged approach was used: (1) data on physician prescribing practices was gathered via retrospective chart review of EoE patients prescribed dupilumab and (2) pediatric patients on dupilumab were approached to complete a questionnaire regarding reasons for initiation. During this time, 42 ...
dependent asthma; as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP), and for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE). ...
A number of studies of dupilumab in other type 2 inflammatory conditions such aschronic sinusitisandnasal polyposis(Bachert, Gevaert, & Hellings, 2017; Beck et al., 2014) andatopic dermatitis(Thaci et al., 2016; Worm et al., 2020). For example, two phase 3 trials with identical design ...
In addition to the currently approved indications, Regeneron andSanofiare studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including pediatric EoE, chronic spontaneous urticaria, chronic pruritus of unknown origin, chro...
AstraZeneca’s Truqap Redeems Itself with Phase III Prostate Cancer Win November 26, 2024 · 2 min read · Tristan Manalac Neurodegenerative disease Biohaven Drug Misses in Phase III for SMA, Will Be Tested in Obesi...
Eosinophilic Esophagitis:DUPIXENT is indicated for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Prurigo Nodularis:DUPIXENT is indicated for the treatment of adult patients with prurigo nodularis (PN). ...
One Year Into Dupilumab: Physician and Patient Experiences in Initiating Dupilumab for Pediatric Eosinophilic Esophagitis In 2022, the US Food and Drug Administration approved dupilumab for treatment of eosinophilic esophagitis (EoE). The aims of this study were to report phys... N Nguyen,C Burger,...
Owing to its chronic course with repeated relapses, it can lead to developmental delays due to malnutrition, especially in pediatric patients. No established treatment exists for non-EoE-EGID, necessitating long-term systemic corticosteroid administration. Although the efficacy of dupilumab, an anti-IL...
Dupilumab is a new therapy approved for the treatment of EoE in adolescents and pediatric patients. The patient experienced significant improvement in gastrointestinal symptoms while on the medication, but developed paresthesias in his legs and torso after several months of use. The symptoms res...